One of the largest pharmaceutical companies in the Australasia region, with a comprehensive portfolio of medicines comprising Regional Brands, including prescription and over-the-counter products, as well as Sterile Focus Brands. A widely-accredited manufacturing facility is operated in Australia, producing finished dose form (“FDF”) solids, liquids and semi-solids as well as packaging for third party contract manufacturing for domestic and export markets.
|Eltroxin/Eutroxsig/Oroxine||Thyroid hormone replacement
NUMBER OF PERMANENT EMPLOYEES
Number of products launched:
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
|Total Commercial Pharmaceuticals||4 867||4 623||5|
|Regional Brands||4 113||3 876||6|
|Sterile Focus Brands||754||747||1|
|Manufacturing – FDF||554||430||29|
|Total||5 421||5 053||7|
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.
- The Australian and New Zealand pharmaceutical market combined, grew 1,9% and was valued at AUD20,7 billion MAT* to May 2021.
Source: IQVIA – August 2020
*MAT = Moving annual total